<DOC>
	<DOCNO>NCT02537379</DOCNO>
	<brief_summary>This post-marketing surveillance ( PMS ) study Sovaldi速 tablet ( sofosbuvir , SOF ) administer combination Copegus速 tablet ( ribavirin , COPE ) evaluate safety efficacy SOF administer combination ribavirin real world use Japan . Among adult patient chronic genotype 2 hepatitis C virus ( HCV ) infection treat SOF+ribavirin routine clinical use , primary objective study evaluate incidence adverse drug reaction ( ADRs ) real world setting .</brief_summary>
	<brief_title>Use-Results Surveillance Study Sovaldi速 Plus Copegus速 Japanese Patients With Chronic Genotype 2 Hepatitis C Virus Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<criteria>Key Adult patient serogroup 2 ( genotype 2 ) chronic HCV infection without compensated cirrhosis Patients prescribe SOF+COPE Key Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hepatitis C virus</keyword>
	<keyword>observational</keyword>
	<keyword>post-marketing</keyword>
	<keyword>sofosbuvir</keyword>
</DOC>